

Tandler PJ, Zaya MJ. Developmental expression of the major human hepatic CYP3A enzymes. *J Pharmacol Exp Ther.* 2003; 307(2): 573–582.

18. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. *J Pharmacol Exp Ther.* 2003; 307(1): 402–407.

19. Gade C, Dalhoff K, Petersen TS, et al. Higher chlorzoxazone clearance in obese children compared with nonobese peers. *Br J Clin Pharmacol.* 2018; 84(8): 1738–1747.

20. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J.* 2005; 5(1): 6–13.

21. Buzková H, Pechandová K, Šlanar O, Perlík F. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. *Cell Biochem Funct.* 2008; 26(1): 76–81.

22. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. *Psychosomatics.* 2003; 44(6): 515–520.

23. Stamer UM, Stüber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. *Anaesthesia.* 2007; 62(12): 1294–1295.

24. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. *J Am Acad Child Adolesc Psychiatry.* 2007; 46(2): 242–251.

25. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet.* 2006; 368(9536): 704.

26. Ginsberg G, Slikker W Jr, Bruckner J, Sonawane B. Expression Incorporating children's toxicokinetics into a risk framework. *Environ Health Perspect.* 2004; 112(2): 272–283.

27. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. *J Pharmacol Exp Ther.* 2004; 308(3): 965–974.

28. Cashman JR, Zhang J. Human flavin-containing monooxygenases. *Annu Rev Pharmacol Toxicol.* 2006; 46: 65–100.

29. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. *Pharmacol Ther.* 2005; 106: 357–387.

30. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. *Pediatr Res.* 2002; 51(2): 236–243.

31. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. *J Pharmacol Exp Ther.* 2002; 300: 361–366.

32. FDA: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Content current as of: 03/10/2020 Available from: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300105&Ing=en&nr-m=iso>.

33. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. *J Pharmacol Exp Ther.* 2002; 300(2): 355–360.

34. Ladumor MK, Bhatt DK, Gaedigk A, et al. Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism. *Drug Metab Dispos.* 2019; 47(8): 818–831.

35. Sunderland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. *Am. J. Dis. Child.* 1959; 97: 761–767.

36. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2010; 154(2): 103–116.

37. Pacifici GM, Säwe J, Kager L, Rane A. Morphine glucuronidation in human fetal and adult liver. *Eur J Clin Pharmacol.* 1982; 22(6): 553–558.

38. Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. *Am J Health Syst Pharm.* 2019; 76(19): 1472–1480.

39. Kodidela S, Kumar SS, Uppugunduri CR. Developmental pattern of hepatic drug-metabolizing enzymes in pediatric population and its role in optimal drug treatment. *Arch Med Health Sci.* 2017; 5: 115–122.

40. Cummings ED, Kong EL, Edens MA. Gray Baby Syndrome. [Updated 2020 Sep 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448133/>.

41. Golka K, Selinski S. NAT2 Genotype and Isoniazid Medication in Children. *EBioMedicine.* 2016; 11: 11–12.

42. Knowles JW, Xie W, Zhang Z, et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. *J Clin Invest.* 2015 Apr; 125(4): 1739–1751.

43. Kamel AM, Ebid GT, Moussa HS. N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia. *Tumour Biol.* 2015; 36(8): 6341–6348.

44. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. *Toxicology.* 2003; 192(1): 37–48.

45. Fakhoury M, Litalien C et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. *Drug Metab Dispos.* 2005; 33(11): 1603–1607.

46. Lee KB, Ang L, Yau WP, Seow WJ. Association between

Metabolites and the Risk of Lung Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies. *Metabolites.* 2020; 10(9): 362.

47. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. *Toxicology.* 2003; 192(1): 37–48.

48. Martin JRN, SLHD Guideline: Newborn Infants Exposed to SSRI / SNRI Antidepressant Medication during Pregnancy and Lactation, Sydney Local Health District, 2020.

49. Kelly EL, Poon S, Madadi P, Koren G. Neonatal Benzodiazepines Exposure during Breastfeeding. *J Pediatr.* 2012; 161(3): 448–451.

50. Kimmel MC, Meltzer-Brody S. Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding, UpToDate, 2020.

51. Lee J. Antiepileptic Drugs in Children: Current Concept. *J Korean Neurosurg Soc.* 2019; 62(3): 296–301.

52. Sridharan K, Daylami AA, Ajawi R, Ajooz HAMA. Drug-Induced Liver Injury in Critically Ill Children Taking Antiepileptic Drugs: A Retrospective Study. *Curr Ther Res Clin Exp.* 2020; 92: 100580.

53. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. *Br J Anaesth.* 2019; 122(4): 448–459.

54. Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. *Crit Care.* 2015; 19: 398.

55. Hassen M, Bhikoo R, Clint J, Yazied C. Unintentional diethylene glycol poisoning following the consumption of a shared alcoholic beverage. *African Journal of Nephrology.* 2018; 21(1): 8–11.

56. O'Brien KL, Selanikio JD et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. *Acute Renal Failure Investigation Team. JAMA.* 1998; 279(15): 1175–1180.

57. Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmitt G. Pediatric Safety of Polysorbates in Drug Formulations. *Children (Basel).* 2019; 7(1): 1.

58. Valeur KS, Holst H, Allegaert K. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. *Pharmaceut Med.* 2018; 32(4): 251–258.

59. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. *Clin Pharmacokinet.* 2006; 45(11): 1077–1097.

60. Eidelman C, Abdel-Rahman S. Pharmacokinetic considerations when prescribing in children. *Int J Pharmacokin.* 2018; 1(1): 69–80.